A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2019
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2018 Planned initiation date changed from 15 Nov 2018 to 26 Nov 2018.
- 10 Oct 2018 Planned initiation date changed from 30 Oct 2018 to 15 Nov 2018.